Show simple item record

dc.contributor.authorClaassen, C.W.
dc.contributor.authorKeckich, D.
dc.contributor.authorNwizu, C.
dc.date.accessioned2019-09-13T16:41:56Z
dc.date.available2019-09-13T16:41:56Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062070935&doi=10.1177%2f2325958218823209&partnerID=40&md5=979422f502a5dfb2008f5d9347647f2f
dc.identifier.urihttp://hdl.handle.net/10713/10655
dc.description.abstractBackground: Characterizing viral response to lopinavir/ritonavir (LPV/r) monotherapy as second-line treatment may guide recommendations for resource-limited settings (RLS). Methods: We conducted a 48-week prospective, single-arm study of LPV/r monotherapy in patients failing first-line therapy in Nigeria. The primary outcome was sustained HIV-1 viral load (VL) <400 copies/mL at 48 weeks. Results: Of 30 enrolled patients, 28 (93%) achieved viral suppression on LPV/r, while 29 (96%) experienced low-level viremia. At 48 weeks, 9 (30%) met the primary outcome of sustained viral suppression; 14 (47%) patients were suppressed on LPV/r in a snapshot analysis. Detectable VLs at 12 and 24 weeks were strongly associated with treatment failure at 48 weeks. New resistance mutations were not detected. The trial was stopped early due to treatment failure. Conclusion: In this study, the rate of virologic failure among patients on a second-line lopinavir monotherapy regimen was relatively high and predicted by early detectable viremia. However, no LPV/r-associated resistance mutations were detected despite fluctuating low-level viremia, demonstrating the high genetic barrier to resistance of the protease inhibitor class which could be useful in RLS.en_US
dc.description.urihttps://doi.org/10.1177/2325958218823209en_US
dc.language.isoen-USen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofJournal of the International Association of Providers of AIDS Care
dc.subjectboosted protease inhibitor monotherapyen_US
dc.subjectHIVen_US
dc.subjectlopinavir/ritonavir monotherapyen_US
dc.subjectresource-limited settingsen_US
dc.subjectsecond-line antiretroviral therapyen_US
dc.titleHIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1177/2325958218823209
dc.identifier.pmid30798695


This item appears in the following Collection(s)

Show simple item record